eligibility_summary
Informed consent required. Adults (>=18) with WHO-confirmed, relapsed/refractory CD20+ mantle cell lymphoma after >=1 prior regimen, ECOG <=2, measurable/active disease, adequate marrow/organ function, LVEF >=40%, O2 sat >=92%, provide tumor tissue, contraception. Exclude: prior T-cell bispecifics, >180 days or progression on BTKi, recent chemo/antibody/radiation/CAR-T/HSCT/major surgery, strong CYP3A4 drugs, CNS disease, active infection, major cardiac/GI/bleeding disorders, transplant, pregnancy, live vaccines, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in relapsed/refractory mantle cell lymphoma tests: 1) Acalabrutinib (oral small‑molecule Bruton tyrosine kinase [BTK] inhibitor): blocks B‑cell receptor (BCR) signaling, reducing survival/proliferation of malignant B cells. 2) Obinutuzumab (IV type II anti‑CD20 monoclonal antibody): targets CD20 on B cells to induce direct cell death and immune effector killing (ADCC/ADCP, some CDC). 3) Glofitamab (IV CD20×CD3 bispecific antibody): simultaneously binds CD20 on lymphoma cells and CD3 on T cells, redirecting and activating T cells to kill B cells. Targets/cells/pathways: CD20+ mantle cell lymphoma B cells, BTK/BCR signaling pathway, CD3+ T cells (T‑cell engagement/activation and cytotoxicity). Combination aims to suppress BCR signaling, deplete CD20+ cells, and drive T‑cell–mediated tumor lysis.